Last updated: April 19, 2023
Sponsor: Innovo Therapeutics, Inc.
Overall Status: Active - Recruiting
Phase
2
Condition
N/ATreatment
INV-001
Clinical Study ID
NCT05838833
INV001-01
Ages > 19 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patient who got thyroidectomy due to Thyroid cancer
- has scar longer than 3 cm
Exclusion
Exclusion Criteria:
- have history about Keloid or Hypertrophic scar
- have infection on surgical site
Study Design
Total Participants: 75
Treatment Group(s): 1
Primary Treatment: INV-001
Phase: 2
Study Start date:
February 14, 2023
Estimated Completion Date:
June 30, 2024
Study Description
Connect with a study center
Innovo Therapeutics, Inc.
Seoul,
Korea, Republic ofActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.